Legal Opinion
In re Invokana (CANAGLIFLOZIN) Products Liability Litigation
United States Judicial Panel on Multidistrict Litigation
Decided December 7, 2016No. MDL No. 2750PublishedCited by 8 opinions
1Opinion of the Court
TRANSFER ORDER
Sarah S. Vance, Chair
Before the Panel: * Plaintiffs in 29 actions pending in the District of New Jersey move under 28 U.S.C. § 1407 to centralize this litigation in that district. The *1347litigation consists of 55 actions, as listed on the attached Schedule A. The Panel has been informed of 44 additional related federal actions.1
The 55 actions involve allegations that ingestion of the drug Invokana may cause a variety of injuries, including diabetic ke-toacidosis and kidney damage, and that defendant Janssen Pharmaceuticals, Inc. (Janssen), which developed and manufactured the drug,…
2Cases cited2 opinions
- In re Watson Fentanyl Patch Products Liability LitigationUnited States Judicial Panel on Multidistrict Litigation · 2012
- In re Yellow Brass Plumbing Component Products Liability LitigationUnited States Judicial Panel on Multidistrict Litigation · 2012
3Cited by8 opinions
- In re Generic Digoxin & Doxycycline Antitrust LitigationUnited States Judicial Panel on Multidistrict Litigation · 2017
- In re Proton-Pump Inhibitor Products Liability LitigationUnited States Judicial Panel on Multidistrict Litigation · 2017
- In re: Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Liability LitigationDistrict Court, W.D. Pennsylvania · 2026
- In re: Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Liability LitigationDistrict Court, N.D. California · 2026
- Jones v. Novo Nordisk A/SDistrict Court, D. Idaho · 2024
3 more not listed; retrieve them via the Exa API.